SCHEMBL3083268

SCHEMBL3083268

COC(=O)C(Cc1ccccc1)NC(=O)c1cnccn1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSL P07711 1/20 0.69
LONP1 P36776 12/20 0.65
PSMB5 P28074 11/20 0.65
PSMB8 P28062 10/20 0.65
PSMB9 P28065 10/20 0.65
PSMB6 P28072 10/20 0.65
PSMB10 P40306 10/20 0.65
PSMB11 A5LHX3 9/20 0.65
PSMA7 O14818 9/20 0.65
PSMB1 P20618 9/20 0.65
PSMA1 P25786 9/20 0.65
PSMA2 P25787 9/20 0.65
PSMA3 P25788 9/20 0.65
PSMA4 P25789 9/20 0.65
PSMA5 P28066 9/20 0.65
PSMB4 P28070 9/20 0.65
PSMB3 P49720 9/20 0.65
PSMB2 P49721 9/20 0.65
PSMA6 P60900 9/20 0.65
PSMA8 Q8TAA3 9/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2125371 1.00 CTSL (0.69) CTSLLONP1PSMB5PSMB8PSMB9
SCHEMBL2126526 0.95 LONP1 (0.70) CTSLLONP1PSMB5PSMB8PSMB9
SCHEMBL2126477 0.91 LONP1 (0.64) CTSLLONP1PSMB5PSMB8PSMB9
SCHEMBL2127175 0.91 LONP1 (0.64) CTSLLONP1PSMB5PSMB8PSMB9
SCHEMBL2127966 0.91 PSMB5 (0.69) CTSLLONP1PSMB5PSMB8PSMB9
SCHEMBL21974787 0.90 CTSL (0.65) CTSLLONP1PSMB5PSMB8PSMB9
SCHEMBL27895591 0.89 LONP1 (0.64) CTSLLONP1PSMB5PSMB8PSMB9
SCHEMBL27895590 0.89 LONP1 (0.64) CTSLLONP1PSMB5PSMB8PSMB9
SCHEMBL20250626 0.89 CTSL (0.64) CTSLLONP1PSMB5PSMB8PSMB9
SCHEMBL28766228 0.89 CTSL (0.64) CTSLLONP1PSMB5PSMB8PSMB9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103059054-A Synthetic method of bortezomib HANGZHOU PING HE AN KANG PHARMACEUTICAL CO LTD 2013-04-24 CN claimed
CN-103059054-A Synthetic method of bortezomib HANGZHOU PING HE AN KANG PHARMACEUTICAL CO LTD 2013-04-24 CN disclosed
US-20100226597-A1 BORTEZOMIB AND PROCESS FOR PRODUCING SAME DR. REDDY'S LABORATORIES LIMITED (IN) 2010-09-09 US disclosed
EP-2185159-A2 BORTEZOMIB AND PROCESS FOR PRODUCING SAME Dr. Reddy's Laboratories, Ltd. (IN) 2010-05-19 EP disclosed
WO-2009036281-A2 BORTEZOMIB AND PROCESS FOR PRODUCING SAME DR. REDDY'S LABORATORIES LTD. (IN) 2009-03-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100226597-A1 BORTEZOMIB AND PROCESS FOR PRODUCING SAME PSMC1, PSMB4, PSMB1 CTSL 723/4885LONP1 505/4885PSMB5 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.